/
Other
Safety and Efficacy
130
Pipeline Programs↗
163
Active Trials↗
316
Companies Involved↗
Safety and Efficacy is a highly competitive landscape with 130 programs across 316 companies. The most active players are A2 Biotherapeutics Inc., Gilead, AstraZeneca. 25 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical23
Phase 119
Phase 263
Phase 325
Approved
No programs
Analysis
Modality Breakdown
83%
Small molecule
91 of 110 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 110 classified programs, each share of the total. Modality classified for 100% of 130 pipeline programs.
Analysis
Trial Status
1,678
clinical trials
Completed1,098 · 65%
Unknown status179 · 11%
Terminated169 · 10%
Recruiting91 · 5%
Withdrawn58 · 3%
Active, not recruiting42 · 3%
Other41 · 2%
Clinical Trials
Trial Activity
1678 trials
The Safety and Efficacy of Coenzyme I for Injection in Promoting Hematopoietic Recovery of Patients After sUCBT
Recruiting·—·Phase 1·NCT06558253·12 enrolled
Safety and Efficacy of Mitoxantrone Hydrochloride Liposome Based DCMG Regimen for R/R AML
Recruiting·—·Phase 2·NCT06741722·20 enrolled
Evaluating the Safety and Efficacy of Oral Encapsulated Microbiota Transplantation Therapy in Peanut Allergic Patients
Recruiting·—·Phase 2·NCT05695261·37 enrolled
Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r DLBCL Clinical Research
Recruiting·—·Phase 1·NCT06120166·18 enrolled
Page 1 of 112
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)